Status
Conditions
About
Longitudinal prospective monocentric observational study in which patients to start Mirikizumab for normal clinical practice will be followed for 24 weeks. Based on the findings in the comparison between US (IUS and TPUS) and endoscopy, the study aim is to build up a modified MUC (Milan Ultrasound Criteria) scoring system taking each colonic segment and the rectum into account, developing non-invasive quantitative ultrasound-based criteria to identify patients with active UC and assess its severity.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Age ≥ 18 years
Confirmed diagnosis of UC according to ECCO guidelines
Patients with active moderate-to-severe disease defined as MES
≥ 2
Patients undergoing advanced therapies with mirikizumab according to clinical judgement
Patients who provide written informed consent
Exclusion criteria
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal